Accuri Cytometers Completes $6M Series E Financing

Accuri Cytometers, Inc., an Ann Arbor, MI-based developer and provider of flow cytometers to life science researchers, completed a $6m Series E preferred stock financing.
The round included existing investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.
The company will use the funds to support expansion of its cell analysis system, the Accuri C6 Flow Cytometer®, into the clinical in vitro diagnostics (IVD) market.
Commenting on the funding, Jeffrey Williams, President and CEO of Accuri, was quoted as saying: “Fueled by our continued sales growth in the U.S. and Europe and our recent expansion into international markets in Asia and South America, Accuri is now one of the fastest growing cell analysis companies worldwide. 
“This financing round will enable us to respond to a rising number of requests for an Accuri flow cytometer for clinical diagnostic applications, providing the same benefits of high performance, cost-effectiveness and ease-of-use experienced by our life science research customers”, he added.
The company is currently implementing an ISO13485 Quality System in preparation for the European launch of the Accuri C6 Flow Cytometer with CE-IVD mark certification for clinical use.
This will be followed by a 510 (K) regulatory submission to the FDA seeking clearance to market the same product for clinical IVD applications in the U.S.



Join the discussion